
BIOGRAPHICAL SKETCH

NAME Kathleen T. Finn		POSITION TITLE Director, Cancer Clinical Research & Cancer Support Programs	
EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Massachusetts, Boston, MA.	B.S.N.	1983	Nursing
Simmons College of Health Sciences, Boston, MA.	M.S.N, A.N.P	1998	Nursing/Adult Nurse Practitioner

A. Positions and Honors. List in chronological order previous positions, concluding with your present position. List any honors. Include present membership on any Federal Government public advisory committee.

1983-1984: Medical Staff Nurse. Boston City Hospital, Boston, MA
1984-1989: Oncology/Hematology Staff Nurse. University Hospital, Boston, MA
1989-1993: Psychiatric Staff Nurse, Intensive Treatment Unit. Bournewood Hospital, Brookline, MA
1989-1992: Clinical Research Nurse in Hematology and Oncology. University Hospital, Boston, MA
1992-1996: Clinical Research Nurse, Cancer Research Center Boston Univ. Med. Ctr Hospital, Boston, MA
1994-pres: Nurse Manager, Autologous Stem Cell Transplant Program, Boston Medical Center, Boston, MA
1996-2005: Clinical Research Manager, Clinical Trials Office,
1998-pres: Nurse Manager Advance Practice Nurse/Clinical Trials Office
2001-pres: Manager, Cancer Education & Early Detection Community Outreach Program
2005-pres: Director; Cancer Clinical Trials Cancer Research Center, Boston Medical Center, Boston, MA
2006-pres: Director, Cancer Support Services, Boston Medical Center, Boston, MA

HONORS/MEMBERSHIPS/CERTIFICATIONS

1986: Member, Oncology Nursing Society
1986- pres: Member, Boston Oncology Nursing Society
1994: Oncology Nursing Society Certification
1996: Great Expectations Award, Southwest Oncology Group
1998: American Nurses Credentialing Center Certification as an Adult Nurse Practitioner
1999: Advanced Oncology Nursing Society Certification
2003: Advanced Oncology Nursing Society Recertification
2003: American Nurses Credentialing Center/Adult Nurse Practitioner Recertification
2008: American Nurses Credentialing Center/Adult Nurse Practitioner Recertification
2008: Advanced Oncology Nursing Society Recertification

COMMITTEES

1991-1996: Cancer Care Committee, University Hospital, Boston, MA
1991-1996: Cancer Care Committee, Boston City Hospital, Boston, MA
1993-pres: Nurse Oncology Committee, Southwest Oncology Group
1996-pres: Cancer Care Committee, Boston University Medical Center
1999-pres: Hematology/Oncology Quality Improvement Committee, Boston Medical Center
2002-2003: Co-Chair, Hematology/Oncology Quality Improvement Committee, Boston Medical Center
2004-pres: Chair, Hematology/Oncology Quality Improvement Committee, Boston Medical Center
2005-pres: Cancer Care Committee, Outreach Subcommittee
2005-pres: Cancer Care Committee, Quality Improvement Subcommittee

B. Selected peer-reviewed publications

ARTICLES

1. Comenzo, RL, Vosburgh, E, Simms, RW, Bergethon, P, Sarnacki, D, **Finn, K**, Dubrey, S, Faller, DV, Wright, DG, Falk, R, Skinner, M: Dose-intensive melphalan with blood stem-cell support for the treatment of AL amyloidosis: One-year follow-up in five patients. *Blood* 88:2801-2806, 1996.
2. Comenzo, RL, Santhorawala, V, Fisher, C, Akpek, G, Farhat, M, Cerda, S, Berk, JL, Dember, LM, Falk, R, **Finn, K**, Skinner, M, Vosburgh, E: Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. *British Journal of Haematology*, 104, 553-559, 1999.
3. Comenzo R, Vosburgh E, Falk R, Fisher C, **Finn K**, Dember L, Berk J, Akpek G, Santhorawala V, Skinner M: High-Dose Melphalan for AL amyloidosis: Outcomes in 50 Patients. *Amyloid and Amyloidosis*. Ed. by RA Kyle and MA Gertz, Parthenon Publishers, New York, 1999. Pp 99-101.
4. Santhorawala V, Wright DG, Seldin DC, Dember LM, **Finn K**, Falk RH, Berk J, Quillen K, Skinner M: An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. *Bone Marrow Transplantation*, 2001; 28(07):637-642
5. Santhorawala V, Wright DG, Seldin DC, Falk RH, Berk JL, Dember LM, **Finn KT**, Skinner M. Low dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. *British Journal of Haematology* 2002.
6. Seldin DC, Choufani EB, Dember LM, Wiesman J, Berk JL, Falk RH, O'Hara C, Fennessey S, **Finn KT**, Wright DG, Skinner M, and Santhorawala V. Tolerability and Efficacy of Thalidomide for Treatment of Patients with AL Amyloidosis. *Clinical Lymphoma* 2003; 3 (4): 241-246
7. Skinner M, Santhorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, **Finn KT**, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG. High-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis: An 8-year study. *Annals of Internal Medicine* 2004; 140: 85-93.
8. Santhorawala V, Wright DG, Seldin DC, Falk RH, **Finn KT**, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. *Bone Marrow Transplantation* 2004; 33 (4): 381-388.
9. Seldin DC, Anderson JJ, Santhorawala V, Malek K, Wright DG, Quillen K, **Finn KT**, Berk JL, Dember LM, Falk RH, Skinner M. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. *Blood* 2004; 104 (6): 1888-1893.
10. Oran B, Malek KM, Santhorawala V, Wright DG, Quillen K, **Finn KT**, LaValley M, Skinner M, Seldin DC. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. *Bone Marrow Transplantation* 2005; 35: 567-575.
11. Santhorawala V, Wright DG, Quillen K, Kunz R, **Finn KT**, Malek K, Falk RH, Berk JL, Dember LM, Skinner M, Seldin DC. Treatment of AL amyloidosis with tandem cycles of high dose melphalan and autologous stem cell transplantation. In *Amyloid and Amyloidosis*, Ed by G Grateau, RA Kyle, M Skinner, CRC Press, Boca Raton, pp 124-126, 2005.
12. Seldin DC, Santhorawala V, Malek K, Wright DG, Quillen K, **Finn KT**, Falk RH, Berk JL, Dember LM, Wiesman J, Anderson J, Skinner M. High dose melphalan and autologous stem cell transplantation (HDM/SCT) for treatment of AL amyloidosis: ten year single institutional experience. In *Amyloid and Amyloidosis*, Ed by G Grateau, RA Kyle, M Skinner, CRC Press, Boca Raton, pp 160-162, 2005.
13. Seldin, DC, Anderson, JJ, Skinner, M, Malek, K, Wright, DG, Quillen, K, **Finn, KT**, Oran, B, Santhorawala, V. Successful Treatment of AL Amyloidosis Patients Over Age 65 with High-Dose Melphalan and Autologous Stem Cell Transplantation. *Blood* 2006; 108 (12):3945-3947

14. Sanchorawala, V, Wright, DG, Rosenzweig, M, **Finn, K**, Fennessey, S, Zeldis, J, Skinner, M, Seldin, DC. Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Results of a Phase II Trial. *Blood* 2007; 109 (2): 492-496 {Pre-published online as a Blood First Edition Paper on Sept 7, 2006}
15. Sanchorawala V, Wright DG, Quillen K, **Finn KT**, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC. Tandem cycles of high dose melphalan and autologous stem cell transplantation increased the response rate in AL amyloidosis. *Bone Marrow Transplantation*

ABSTRACTS/POSTERS

1. Comenzo, RL, Farhat, M, **Finn, K**, Vosburgh, E, Wright, DG, Arkin, CF: G-CSF mobilization and blood stem cell collection and use in patients with AL amyloidosis. *Blood*. 88:406a, 1996.
2. Comenzo, RL, Sarnacki, D, Farhat, M, Cerda, S, Sanchorawala, V, **Finn, K**, Skinner, M, Falk, R, Vosburgh, E: Sequential GM + G-CSF versus G-CSF for blood stem cell mobilization in AL amyloidosis. *Blood*. 88:406a, 1996.
3. Comenzo, RL, Sarnacki, D, **Finn, K**, Falk, R, Sanchorawala, V, Akpek, G, Farhat, M, Vosburgh, E: AL amyloidosis responds to high dose melphalan and blood stem cells. *Blood*. 88:686a, 1996.
4. Comenzo RL, Sarnacki D, **Finn K**, Falk R, Sanchorawala V, Akpek G, Farhat M, Vosburgh E: Treating Amyloidosis with high-dose melphalan and blood stem cells. *Blood* 1996; 88(10): 686a
5. Comenzo RL, Falk R, Reisling J, Dubrey S, **Finn K**, Sarnacki D, Berk J, Dember LM, Bergethon P, Sanchorawala V, Vosburgh E, Skinner M: AL amyloidosis frequently remits after dose intensive melphalan with blood stem cell support: Outcomes in 55 patients. Presented at the International Myeloma meeting, 1997.
6. Sarnacki, D, **Finn, K**: Nursing implications for the treatment of primary (AL) amyloidosis: high dose melphalan and blood stem cell rescue. Poster Presentation -Sixth Annual Seattle Marrow Transplant Nursing Consortium, 10/2-4/97.
7. Skinner M, **Finn K**, Comenzo R, Vosburgh E, Sanchorawala V, Akpek G, Spellane K, Falk R, Dember L, Berk J, Murakami A, Libbey C, Wright D: Four year experience with high dose IV melphalan and peripheral stem cell rescue in AL amyloidosis. *Arthritis and Rheumatism*, Vol. 41, s233, 1998.
8. Comenzo, RL, Sarnacki, D, Farhat, M, Flanagan MB, **Finn, K**, Vosburgh, E, Skinner, M, Dubrey, S, O'Hara, C, Wright, DG, Arkin, CF: Parameters of blood stem-cell mobilization and collection on patients with AL amyloidosis. Submitted.
9. Comenzo RL, Falk RH, Sanchorawala V, Seldin DC, Akpek G, Malek K, Vosburgh E, Dember L, Berk J, **Finn K**, Fisher C, Wright DG, Skinner M: Treating AL Amyloidosis with dose-intensive melphalan: outcomes in 102 patients. *Blood* 1998; 92(10): 324a
10. Sanchorawala V, Wright DG, Dember LM, Seldin DC, Vosburgh E, **Finn K**, Fisher C, Murakami A, LaValley M, Akpek G, Taper J, Falk RH, Berk J, Skinner M: Five years experience with high dose intravenous melphalan and autologous peripheral blood stem cell transplantation for the treatment of patients with AL amyloidosis. Presented at IBMTR/ABMTR Conference, 2000.
11. Seldin DC, Choufani E, Skinner M, Wright DG, Dember LM, Weisman J, Fennessey S, **Finn KT**, Sanchorawala V. A phase I/II trial of thalidomide for patients with AL amyloidosis. *Blood* 2001; 98(11): 164a
12. Sanchorawala V, Wright DG, Seldin DC, Falk RH, **Finn KT**, Dember LM, Berk JL, Quillen K, Wright EC, Comenzo RL, Skinner M. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. *Blood* 2001; 98(11): 815a
13. Sanchorawala V, Taper J, Seldin DC, Falk RH, Dember LM, Berk J, **Finn KT**, Quillen K, Skinner M, Wright DG. High dose intravenous melphalan and autologous stem cell transplantation for the treatment of AL amyloidosis: morbidity and mortality. *Blood* 2001; 98(11): 860a

14. Sanchorawala V, Wright DG, Seldin DC, **Finn KT**, Skinner M. Low dose continuous oral melphalan for the treatment of AL amyloidosis. *Blood* 2001; 98(11): 311b
15. Sanchorawala V, Wright D, Seldin D, Dember L, **Finn K**, Falk R, Berk J, Quillen K, Skinner M. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. *Bone Marrow Transplantation* 2001; 28(07): 637-642.
16. Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, **Finn K**, Skinner M, Seldin DC. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for treatment of AL amyloidosis. *Blood* 2003; 102 (11): 708a
17. Sanchorawala V, Wright DW, Seldin DC, Falk RH, **Finn KT**, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M: High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. *Bone Marrow Transplantation*, 2003.
18. Baribeault D, **Finn K**, Seldin D, Sanchorawala V. A retrospective comparison of the impact of darbepoetin or epoetin usage on PRBC transfusions in autologous SCT for AL Amyloidosis., ASBMT National Meeting February 2004
19. **Finn K**, Sanchorawala V, Seldin D, Kunz R, Quillen K. Long-term, apheresis/hemodialysis catheters decrease the incidence of catheter-related blood stream infections and venous thrombosis in patients with AL amyloidosis undergoing high-dose melphalan and autologous stem cell transplant. *Biology of Blood and Marrow Transplantation* 2004; 10 (2): 85
20. **Finn K**, Sanchorawala V, Kunz R, Seldin D, Wilkes G, Oran B. Cryotherapy is effective in preventing melphalan-induced oral mucositis in patients with AL amyloidosis. *Biology of Blood and Marrow Transplantation* 2004; 10 (2): 86
21. **Finn K**, Kunz R, Sanchorawala V, Seldin D, Quillen K. Long-term, Apheresis/hemodialysis Catheters Decrease the Incidence of Catheter-Related Bloodstream Infections (CR-BSI) and Venous Thrombosis (VT) in Patients With AL Amyloidosis (AL) Undergoing High-dose Melphalan and Autologous Stem Cell Transplant (HDM/SCT), ASBMT National Meeting February 2004
22. **Finn K**, Sanchorawala V, Kunz R, Wilkes G, Seldin D, Oran B. Cryotherapy (Ice Chips) Is Effective In Preventing Melphalan-induced Oral Mucositis (OM) in Patients With AL Amyloidosis, ASBMT National Meeting February 2004.
23. Baribeault D, **Finn KT**, Kunz R, Seldin D, Sanchorawala V. A retrospective comparison of the impact of darbepoetin or epoetin usage on red cell transfusions in autologous stem cell transplantation for light-chain related amyloidosis. *Biology of Blood and Marrow Transplantation* 2004; 10 (2): 92
24. Quillen K, Wright DG, Seldin DC, Skinner M, Malek KM, **Finn KT**, Sanchorawala V. Feasibility of second autologous peripheral blood stem cell collection followed by a second cycle of high dose melphalan in patients relapsing after an initial course of HDM for the treatment of AL amyloidosis. *Blood* 2004; 104 (11):
25. Sanchorawala V, Seldin DC, Wright DG, Skinner M, **Finn KT**, Falk RH. Pulsed Low Dose Intravenous Melphalan in Patients with AL Amyloidosis, Ineligible for Aggressive Treatment with High-Dose Melphalan and Stem Cell Transplantation. *Blood* 2004; 104 (11):
26. Baribeault, D., Shah, B., **Finn, KT.**, Seldin, D., Quillen, K., Sanchorawala, V. A Retrospective Analysis of the Impact of Erythropoietic Growth Factor Utilization on Transfusion Requirements in Patients with AL Amyloidosis Undergoing Autologous SCT, ASBMT National Meeting February 2006.
27. Sanchorawala, V., Wright, DG., Rosenzweig, M., **Finn, KT.**, Fennessey, S., Skinner, M., Seldin, DC. A Phase II Trial of Lenalidomide In The Treatment of AL Amyloidosis, ASCO National Meeting, June 2006.
28. **Finn, KT.**, Fennessey, S., Yanarella, L., Antonelli, C., Shelton, A., Daniel, S., Skinner, M., Quillen, K., Seldin, D., Sanchorawala, V. 2009 Clinical Pathways and Standard Operating Procedures: Essential Tools for Outpatient Stem Cell Transplant Programs Treating Patients with AL Amyloidosis

BOOKS/CHAPTER

1. Chouinard, M & **Finn, K.** 2006. Hematopoiesis. In Ezzone, S. (Eds). Blood and Marrow Stem Cell Transplantation, 3rd ed. Sudbury, Mass., Jones and Bartlett Publishers, Chapter 4.

ORAL PRESENTATIONS

1. **Finn, K.**, Fennessey, S., Sanchorawala V, Antonelli, C., Shelton, A., Seldin D. Skin reactions associated with oral Revlimid® (lenalidomide) in AL Amyloidosis (ALA); patient teaching encouraging prompt reporting, and clinical assessment and management of skin reactions can impact patient outcomes. Accepted for oral presentation, Oncology Nursing Society National Conference, May 2006.
2. **Finn, K.**, AL Amyloidosis, What the oncology nurse should know. Boston Oncology Nursing Society (CEU credit), June 10, 2008.
3. **Wilkes, G., Finn, K, Veil, C.** AL Amyloidosis: New Cancer on the Block. Oncology Nursing Society National Conference, May 2, 2009.

C. Research Support/Awards/Grants

Lance Armstrong Foundation; “Developing a Cancer Survivorship Program at a Safety Net Hospital”, awarded 12/2005

Patricia Cronin Foundation; “Mind/Body Support Group for Ovarian Cancer Patients”, awarded 6/2006

Patricia Cronin Foundation; “Mind/Body Support Group for Ovarian Cancer Patients”, awarded 6/2007

Patricia Cronin Foundation; “Mind/Body Support Group for Ovarian Cancer Patients”, awarded 6/2008

Paul Newman Charitable Giving; Supplemental Funds for Ovarian Cancer Support awarded 9/2006.

Paul Newman Charitable Giving; Supplemental Funds for Ovarian Cancer Support awarded 9/2007.

Attorney General’s Office; “Cancer Support Services for the Haitian Creole Speaking Population in Boston”, awarded 10/2006